News
BMS’ Opdivo aces trial in asbestos-linked lung cancer
Bristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, getting one up over rival checkpoint inhibitor Keytr
